Croda International AI Stock Analysis
Want to see GB:50GP full AI Analyst Report?
Croda International (50GP) AI Stock Analysis
Croda International
(LSE:50GP)
The overall score of 57 reflects a company with strong operational execution and cash generation, offset by significant valuation and technical headwinds. The most impactful positive factor is the solid financial foundation and confident earnings call, highlighting growth in key segments and margin expansion. However, the stock's extremely high P/E ratio and overbought technical signals present substantial risks, heavily weighing down the score. The mixed financial performance, with margin pressure on the income statement, further contributes to a cautious outlook.
Croda International (50GP) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- GBP 49.46M
- Dividend Yield
- 789.30%
- Average Volume (3M)
- 25.50K
- Price to Earnings (P/E)
- 67.8
- Beta (1Y)
- 0.08
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- UK
- Employees
- 5,954
- Sector
- Basic Materials
- Sector Strength
- 61
- Industry
- Chemicals - Specialty
Croda International Business Overview & Revenue Model
Company Description
Croda International Plc, established in 1925 and headquartered in Goole, United Kingdom, is a global leader in the development, manufacture, and supply of high-performance specialty chemicals. The company serves a diverse international client base ac...
How the Company Makes Money
Croda makes money primarily by selling specialty chemical ingredients and ingredient technologies to business customers (B2B) across consumer care and industrial markets. Its revenue model is largely product sales, where customers pay per unit/volume...
Croda International Earnings Call Summary
The call conveyed a broadly positive performance: underlying sales, EPS and margins improved with clear signs of momentum in innovation-led growth (notably Beauty Actives and Pharma Ingredients), transformation savings are materializing, and strategic capacity expansions in Asia support future growth. Challenges remain—Pharma Solutions timing, Crop Protection weakness, regional/segment softness (North America mass market), working capital outflows and one-off OpEx inflation—but these are presented as manageable or phased rather than structural. Management reiterated full-year guidance (organic sales growth 3–6%) and the 3-year targets through 2028, signaling confidence in execution.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management reiterated unchanged full‑year guidance, forecasting organic sales growth of 3–6% and a further increase in adjusted operating margin, with adjusted operating profit expectations unchanged and FX sensitivities provided; they also said the Q2 exit rate gives confidence in sequential margin improvement in H2 and that the group remains on track for its 3‑year/2028 financial framework. In support, H1 sales were £881m (+5%) with NPP +7%, volumes +1% and price/mix +4%; adjusted operating profit was £156m (+7%) and margin rose to 17.7% (from 17.2%), EPS 78p (+9%), EBITDA £208m, free cash flow £38m (vs £28m), net debt £578m (leverage 1.4x) and an interim dividend of 48p. Management said transformation delivered £18m of H1 savings (cumulative £46m toward a £100m target), CapEx fell to £43m, and a working‑capital program aims for ~£50m of structural savings by 2028 to offset typical annual WC funding of £20–30m.
Croda International Financial Statement Overview
Summary
Financial performance is mixed but resilient. Cash flow generation is a key strength, with robust operating cash flow and a 25% improvement in free cash flow. The balance sheet is solid with low leverage (0.35 debt-to-equity). However, the income statement shows significant gross margin contraction to 35.8% and a sharp drop in net income, which tempers the overall score.
Income Statement
55NeutralBalance Sheet
75PositiveCash Flow
80Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.72B | 1.70B | 1.63B | 1.69B | 2.09B | 1.89B |
| Gross Profit | 615.90M | 608.70M | 733.90M | 730.00M | 864.90M | 825.60M |
| EBITDA | 390.10M | 380.70M | 374.50M | 388.50M | 924.80M | 549.40M |
| Net Income | 79.50M | 62.00M | 158.50M | 171.00M | 649.30M | 320.80M |
Balance Sheet | ||||||
| Total Assets | 3.53B | 3.41B | 3.51B | 3.58B | 3.61B | 3.29B |
| Cash, Cash Equivalents and Short-Term Investments | 205.30M | 172.80M | 166.80M | 172.50M | 320.60M | 112.80M |
| Total Debt | 783.20M | 696.60M | 699.10M | 710.10M | 615.80M | 936.00M |
| Total Liabilities | 1.34B | 1.21B | 1.21B | 1.21B | 1.18B | 1.53B |
| Stockholders Equity | 2.17B | 2.19B | 2.28B | 2.35B | 2.42B | 1.75B |
Cash Flow | ||||||
| Free Cash Flow | 187.80M | 171.80M | 137.60M | 156.80M | 160.90M | 190.50M |
| Operating Cash Flow | 283.40M | 289.50M | 319.40M | 337.50M | 313.30M | 349.20M |
| Investing Cash Flow | -93.00M | -109.80M | -139.10M | -409.80M | 418.10M | -218.40M |
| Financing Cash Flow | -175.90M | -152.60M | -182.60M | -52.40M | -550.90M | -111.90M |
Croda International Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:50GP, the sentiment is Negative. The current price of 74.75 is below the 20-day moving average (MA) of 75.88, below the 50-day MA of 75.86, and below the 200-day MA of 78.14, indicating a bearish trend. The MACD of -0.49 indicates Positive momentum. The RSI at 15.42 is Positive, neither overbought nor oversold. The STOCH value of is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:50GP.
Croda International Peers Comparison
Overall Rating
GB:SYNT60Neutral
GB:VCT59Neutral
GB:50GP57Neutral
GB:JMAT56Neutral
GB:ELM53Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 61Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% |
| 60Neutral | GBP 185.26M | -1.40 | -13.27% | ― | -4.98% | -43.98% | |
| 59Neutral | GBP 795.31M | -37.43 | -4.95% | 3.12% | -1.24% | -166.15% | |
| 57Neutral | GBP 5.42B | 67.75 | 3.65% | 789.30% | ― | ― | |
| 56Neutral | GBP 2.90B | -33.30 | -6.76% | 4.53% | 26.60% | 14.94% | |
| 53Neutral | GBP 1.06B | 18.87 | 11.29% | 1.78% | -11.73% | ― |
* Basic Materials Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:50GP | Croda International (50GP) | 74.75 | 2.52 | 3.49% | |
| GB:ELM | Elementis plc | 186.80 | 34.25 | 22.45% | |
| GB:JMAT | Johnson Matthey (Uk) | 2364.00 | 417.63 | 21.46% | |
| GB:SYNT | Synthomer plc | 102.60 | 52.95 | 106.65% | |
| GB:VCT | Victrex plc | 861.00 | 310.28 | 56.34% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 28, 2026
